Vaxcyte, Inc. Income Statement
PCVX / Health Care|8 years of annual SEC 10-K data (FY2018-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 8 fiscal years. All figures from audited SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.94 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| SG&A Expense | $129.4M | $92.9M | $60.7M | $39.8M | $25.3M | $16.0M | $8.5M | $5.4M |
| R&D Expense | $794.3M | $476.6M | $332.3M | $169.5M | $78.4M | $73.6M | $45.6M | $30.1M |
| Operating Income | -$923.7M | -$569.5M | -$468.0M | -$232.3M | -$103.7M | -$89.6M | -$54.2M | -$35.5M |
| Interest Expense | - | - | $0 | $2.0K | $7.0K | $7.0K | $40.0K | $75.0K |
| Income Tax | $0 | $0 | $0 | - | - | - | - | - |
| Net Income | -$766.6M | -$463.9M | -$402.3M | -$223.5M | -$100.1M | -$89.2M | -$50.3M | -$29.5M |
| EPS (Basic) | -$5.63 | -$3.80 | -$4.14 | -$3.44 | -$1.93 | -$3.02 | - | - |
| EPS (Diluted) | -$5.63 | -$3.80 | -$4.14 | -$3.44 | -$1.93 | -$3.02 | - | - |
| Shares Outstanding | 136.1M | 122.0M | 97.2M | 64.9M | 51.9M | 29.5M | 3.8M | 3.6M |